Madrigal Pharmaceuticals, Inc. (MDGL) Stock
MDGL Key Statistics
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
CEO: William J. Sibold. Company website
MDGL — Frequently Asked Questions
What is the MDGL stock price today?
Madrigal Pharmaceuticals, Inc. (MDGL) trades at $531.52, down 0.54% on the day, as of Sep 20, 2026 14:57 UTC.
What is Madrigal Pharmaceuticals, Inc.'s market cap?
Madrigal Pharmaceuticals, Inc. has a market capitalisation of $12.28B, calculated from the live MDGL share price and shares outstanding.
What is the P/E ratio of MDGL?
MDGL has no meaningful price-to-earnings ratio: Madrigal Pharmaceuticals, Inc. lost $12.89 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Madrigal Pharmaceuticals, Inc. make?
Madrigal Pharmaceuticals, Inc. generated revenue of $1.28B over the trailing twelve months, which puts the stock at 9.56 times sales.
What is the 52-week range for MDGL?
MDGL has traded between $393.61 and $615.00 over the past 52 weeks, and the last price is 13.6% below that high.
Is Madrigal Pharmaceuticals, Inc. profitable?
No. Madrigal Pharmaceuticals, Inc. is loss-making, with a net margin of -25.32% over the trailing twelve months.
What is the analyst price target for MDGL?
Wall Street analysts rate MDGL Buy, with an average price target of $677.00, 27.4% above the current price.
What sector is Madrigal Pharmaceuticals, Inc. in?
Madrigal Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Madrigal Pharmaceuticals, Inc.?
William J. Sibold is the chief executive of Madrigal Pharmaceuticals, Inc., which employs 915 people.
Where can I track MDGL in real time?
QFI Terminal shows MDGL with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See MDGL live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open MDGL in Terminal See plans